Last Week’s Hot Topic on ALS
Last week’s hot topic on ALS was an article titled Biohaven’s ALS Drug Candidate BHV-0223 Receives Positive FDA Feedback written by Magdalena Kegel.
The article is focused on the recently announcement that Portage Biotech and Biohaven Pharmaceuticals have received positive feedback from the U.S. Food and Drug Administration (FDA) on their Pre-Investigational New Drug Application (PIND) interaction regarding Biohaven’s investigative drug BHV-0223, intended for treatment of amyotrophic lateral sclerosis (ALS).
